BioNTech, OncoC4 Report 54% Death Risk Reduction for Lung Cancer Drug Gotistobart

Squamous non-small cell lung cancer has 15% five-year survival rate and 11-month median overall survival, affecting thousands of patients with limited treatment options.

In the long struggle against one of lung cancer's most unforgiving forms, a new compound called gotistobart has emerged from a Chicago conference with data suggesting it may do what few treatments have managed: meaningfully extend life for patients who have already exhausted their options. Developed by BioNTech and OncoC4, the drug works not by poisoning cancer cells but by selectively reawakening the immune system within the tumor itself. For a disease where median survival rarely exceeds eleven months after standard therapies fail, a fifty-four percent reduction in death risk is the kind of

BioNTech, OncoC4 Report 54% Death Risk Reduction for Lung Cancer Drug Gotistobart

Cobertura Relacionada

Receba o Register no seu e-mail